Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells

27 Aug 2020

Abstract excerpt

For many tumor types chemotherapy still represents the therapy of choice and many standard treatments are based on the use of platinum (PT) drugs. However, de novo or acquired resistance to platinum is frequent and leads to disease progression. In Epithelial Ovarian Cancer (EOC) patients, PT-resistant recurrences are very common and improving the response to treatment still represents an unmet clinical need. To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Genomics, phytochemicals, and oxidative stress
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32848212
DOI: 10.1038/s41388-020-01433-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cellsPMID 32848212Read ↗

Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancerSemantic proximity Read ↗

Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cellsSemantic proximity Read ↗

Establishment of panapoptotic gene signatures of platinum-chemotherapy to predict the response of chemotherapeutic drug resistance in gastric cancerSemantic proximity Read ↗

Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer via Integrated Bioinformatics AnalysisSemantic proximity Read ↗

Genome-Wide Mapping of Cisplatin Damaged Gene LociSemantic proximity Read ↗

Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancersSemantic proximity Read ↗

Emerging Roles of SKP2 in Cancer Drug ResistanceSemantic proximity Read ↗

mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAsSemantic proximity Read ↗

Inhibition of ACSS2 triggers glycolysis inhibition and nuclear translocation to activate SIRT1/ATG5/ATG2B deacetylation axis, promoting autophagy and reducing malignancy and chemoresistance in ovarian cancerSemantic proximity Read ↗

Multi-omics characterization of autophagy-related molecular features for therapeutic targeting of autophagySemantic proximity Read ↗

CircHIPK3 contributes to cisplatin resistance in gastric cancer by blocking autophagy‐dependent ferroptosisSemantic proximity Read ↗

GPT2 mediates metabolic alterations in platinum-resistant ovarian cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.